Congresses: Noventure´s remarkable participation at ESPGHAN Congress, May 10 -13, 2017 Prague.

In order to further disseminate its proprietary barrier technology, on which the new concept “mucoprotection” is based, and as part of its continuous investment in its products´ reputation, Noventure has just participated in this year´s ESPGHAN Congress, held in Prague.

Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to the management of GI conditions in children. A record number of such specialists (more than 6.500 delegates) from both European and  non-European countries participated at the congress, and many of them approached Noventure´s stand to request information.

Our products intended for acute diarrhea (Tasectan and Xilaplus, already marketed), as well as our upcoming launch for infant colics, triggered a lot of interest and expectation among doctors.

As usual, representatives from some of Noventure´s preferred partners (this time Onko Kocsel, Lapidot, Valeant and Ferrer) took advantage of our booth to meet and greet there their own customers. 

On top of all that, 2 new posters on 2 clinical trials with Tasectan in Turkey were presented.